Based on pivotal trials and accumulating real-world evidence, PD-1 blockade with cemiplimab now represents the standard first-line systemic option for unresectable locally advanced or metastatic cutaneous squamous cell carcinoma and should be considered early for all eligible patients without major contraindications to immunotherapy. The gene discussed is PDCD1; the disease is cutaneous squamous cell carcinoma.